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ABSTRACT
Even though the increasing incidence of cancer is mainly a consequence of a popula-
tion with a longer life span, part of this augmentation is related to the increasing
prevalence of patients living with a chronic cancer disease. To fight the problem, im-
proved preventive strategies are mandatory in combination with an  innovative
health care provision that is driven by research. To overcome the weakness of transla-
tional research the OECI is proposing a practical approach as part of a strategy fore-
seen by the EUROCAN+PLUS feasibility study, which was launched by the EC in or-
der to identify mechanisms for the coordination of cancer research in Europe.
European cancer research
Cancer is becoming one of the most important chronic diseases and, at the same
time, in a global perspective, according to calculations by the World Health Organiza-
tion, is causing more deaths than AIDS, malaria and tuberculosis together1. 
European cancer research has been thoroughly analyzed in a project financed by
the European Commission after a request of the European Parliament. This project
involved a large number of European cancer centers and other stakeholders and was
reported to the European Commission in early 2008. European cancer research has
often been criticized for being fragmented with insufficient collaboration between re-
search key players. From the political perspective it seems that research has not been
sufficiently coordinated with a focus on improving survival and quality of life for can-
cer patients. In other words, there seems to be a gap between the potential to inno-
vate cancer care and the actual situation in the provision of oncologic care.
The project reports a number of interesting strengths in European cancer re-
search, especially in the global perspective of basic and preclinical cancer research.
There are health care organizations in several countries performing population-
based studies. Some countries have well-developed patient databases. The poten-
tial to establish high quality bio-banks is another advantage especially when elec-
tronically connected to databases with clinical information related to the patient
involved. A number of technical platforms supporting clinical research are avail-
able. Collaborative networks for cancer clinical trials, among which the EORTC (Eu-
ropean Organization for Research and Treatment of Cancer) is the most compre-
hensive one, make Europe an interesting area for the expansion of clinical trials
driven by biological questions. Furthermore, the intellectual capital is impressive
but vulnerable, since it is of interest for research centers outside Europe, often of-
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fering conditions that could attract researchers with
high potential.
Nevertheless, the report points at a number of weak-
nesses, most of which are already known by researchers.
The research process from basic to clinical research is
often fragmented with the consequence that the time
from basic discoveries to clinical implementations of
new diagnostic and treatment methods is too long. The
rapid expansion of new information in cancer biology
together with insufficient communication between ba-
sic and clinical researchers create a gap between basic
and clinical research. Both funding and education are
contributing to maintain this gap. Clinical research in-
volving patients is often more time consuming especial-
ly in relation to the formal aspects and the administra-
tive burden is therefore a bottle neck in the research
process. Another gap is identified in between clinical re-
search and the implementation of new technologies in-
to cancer care. The increasing complexity of research
causes problems in reaching the critical mass for sever-
al types of cancer research leading to unnecessary de-
lays in publishing studies based on adequate series. An
important contributing factor is combining excellent
research with the needs of patients. Cancer care of high
quality is impossible without a multidisciplinary ap-
proach integrating various treatment modalities and di-
agnostic functions. Research adapted to these needs
must be oriented towards this multidisciplinary ap-
proach for effective patient-focused research. Tumor
diseases, although originating in different organs, have
common biological traits such as the dissemination
process. Research on the mechanisms of metastasis for-
mation and its prevention should be the main focus of
cancer research. Within this background, one of the im-
portant conclusions from the Eurocan+Plus project is
that present fragmentation can be overcome through a
more rational integration of the cancer research
process, translational research, and an increased collab-
oration between centers in order to reach the critical
mass for most types of cancer research.
The Comprehensive Cancer Center
The main goals of the activities to combat cancer are
to decrease mortality and morbidity and increase sur-
vival and quality of life. To reach these goals we need
care and prevention which are integrated with research
and education. A type of organization where this inte-
gration is achieved is usually called a comprehensive
cancer centre (CCC). 
A CCC provides patients with care of high quality with
a focus on the needs of patients.
To cover the needs in the total clinical pathway a
number of competences are needed: diagnostic activi-
ties represented by pathology/cytology, imaging and
laboratory medicine, individual molecular diagnosis;
surgical specialities, radiation therapy and medical on-
cology; psychosocial oncology, rehabilitation, support-
ive care and palliative oncology. In a CCC individual fo-
cused prevention and early detection  should be offered
to potential patients.
Research in a CCC should be translational cancer re-
search, which may be defined as a research continuum
from basic through preclinical and clinical research and
implementation and evaluation in the routine care. Or,
as stated by the NCI Translational Research Working
Group, translational research transforms scientific dis-
coveries arising from laboratory, clinical or population
studies into clinical applications to reduce cancer inci-
dence, morbidity, and mortality. The presence of expert-
ise in epidemiology, bio-statistics, bio-informatics in a
CCC should be then considered an added value. 
Education in a CCC aims at all functions in the centre.
Basic education of medical students and nurses as well
as specialist training and continuous medical education
are missions of the CCC. Research education plays a
crucial role, which is an absolute priority if the complex
research process is maintained. The CCC should also
have the role to contribute to educational efforts to im-
prove prevention. Another important function is to sup-
ply decision makers with information on problems and
strategies to improve cancer care. 
A CCC may be a cancer hospital with sufficiently de-
veloped structures for research and education. This is
the case for the most prominent American CCCs and in
some European countries CCCs of this type have been
established. However, in Europe cancer care and re-
search are often part of a university hospital. In this case
the organization is often fragmented and should be im-
proved to form a more visible and identifiable CCC. An
advantage, however, is the close geographic relation-
ship to other disciplines of interest for cancer patients
often suffering from other diseases than cancer. For
both forms of organization there are often hospitals in
the neighborhood taking care of cancer patients. The
OECI’s view is to create the functional network around a
CCC to assure the quality of cancer care and to stimu-
late research collaboration thereby extending the com-
prehensiveness outside the centers. It is important to
emphasize the importance of a strong core containing
highly specialized health care, advanced research re-
sources and structures for education in a comprehen-
sive cancer network.
OECI
The OECI is a non-profit  organization and a Euro-
pean Economic Interest Grouping, thus having a legal
status which is visible within the European Union. It is
the only organization built on cancer centers/institutes
as members linking 58 centers at present. The OECI
main mission is to stimulate the development of CCCs
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in Europe and facilitate collaboration between such
centers. According to the OECI mission statement2 con-
ventional project collaboration between research
groups is  not enough. The increasing complexity in
both the multidisciplinary cancer care and translation-
al research requires a new type of closer collaboration
between centers to put the most important research
questions from the patients perspective in focus. In-
creased research collaboration is necessary to for stud-
ies not only of patients with rare tumors but also of sub-
groups of other patient groups. The expensive infra-
structures needed for modern translational cancer re-
search may be difficult to iterate in all centers. Therefore
we need to share and harmonize structures, for instance
clinical trials units for biologically driven clinical trials,
bio-banks, platforms for biomics, patient data reg-
istries. The need for competences is increasing and
should be shared to a larger extent to include educa-
tional programs.
The OECI has a number of working groups covering
activities supporting the development of comprehen-
siveness. An accreditation methodology for European
CCCs is the mission of one of the groups. A question-
naire regarding quantitative characteristics of cancer
centers, a quality assessment manual and a procedure
for auditing centers will also be used and are presently
part of a pilot study of a limited number of centers. The
methodology will be available for all OECI members in
fall this year. Parallelly, the first step toward a labializa-
tion/designation system will be taken to define the OE-
CI criteria for a European CCC. The next step will be to
develop criteria linked to quality measurements to
identify CCCs of excellence.
A bio-pathology working group is linked to the virtual
European bio-bank, TuBaFrost, which is under the um-
brella of the OECI. Work is ongoing to implement
TuBaFrost in the OECI centers. An educational working
group supports the development of comprehensive-
ness. A working group for new technologies supports
members to improve the infrastructures for radiation
therapy and imaging. For development of clinical
guidelines the OECI is collaborating with the EU project
CoCanCPG.
The OECI is a growing organization. The need to create
closer collaboration between centers is increasing. No
center has the critical mass necessary for most types of
cancer research. Multidisciplinarity is fundamental for
improving cancer care. The research needed for the de-
velopment of multidisciplinary care is complex and this
complexity necessitates the collaboration between CCCs. 
A network of centers. A solution to reach the
critical mass for most types of cancer research
Modern translational research requires new types of
infrastructures, linkage of competences to cover differ-
ent parts of the research process, patients and biologi-
cal materials from increasing subgroups of cancer pa-
tients but also from patients with rare tumor diseases.
For therapy development new molecular targets and
new treatments are needed. To optimize treatments
personalized cancer medicine should be an important
focus for research. Fundamental will be the identifica-
tion of biomarkers for patient and disease characteris-
tics as well as the prediction of response to treatments.
Such a development must be seen in the context of a
multidisciplinary care approach of the patient. The po-
tential to innovate and improve cancer treatment is
spectacular if modern cancer biology, genetic engineer-
ing, methodological developments to use biological
materials from patients and clinical questions are ana-
lyzed in a holistic way. Some of the entities organizing
European cancer centers work, each from a different
perspective, towards establishing a coherent and ad-
vanced level of cancer research.
The OECI has had the objective to stimulate collabo-
ration between centers for a long time. If such collabo-
ration is effective, centers should provide the re-
searchers with infrastructures for translational cancer
research which should be harmonized between centers.
A similar strategy has now been developed and is under
implementation within the EORTC (European Organi-
zation of Research and Treatment of Cancer) – NOCI
(Network Of Core Institutions). This network aims at a
formal collaboration between a limited number of cen-
ters with a substantial number of patients and strong
infrastructures for translational research to conduct bi-
ologically driven clinical trials.
An important conclusion of the Eurocan+Plus project
was to propose the formation of a European transla-
tional research platform by linking the most research
oriented CCCs and basic/preclinical cancer research
centers. Such platform should provide Europe with a
cancer research infrastructure where the European re-
search strengths can be used in a rational way. On No-
vember 6, 2007, representatives of 19 European centers
met in Stockholm to discuss this concept and the dis-
cussion resulted in the “Stockholm Declaration”3. A
number of objectives of the platform were identified: to
define and coordinate specific areas for research collab-
oration; to harmonize and share infrastructures and
competences; to optimize information exchange be-
tween centers; to improve mobility of researchers with-
in the platform; to develop research education in order
to attract young investigators and retain them in Eu-
rope; and to speak for translational cancer research with
one voice in Europe.
A platform of this type must be dynamic. It may start
small but have the potential to grow. The platform shall
be open so new centers can join in future, and through
the dissemination of information the platform will be of
value also for centers outside the platform. A well or-
ganized translational cancer research platform should
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represent a “world-class infrastructure” which is pro-
posed in the Green Paper, a strategic document from
the European Commission. It is interesting that the ma-
jority of the centers behind the Stockholm Declaration
are members of the OECI. Further, it was decided that
the OECI accreditation methodology will be used to
identify criteria for an objective selection of centers for
the platform.
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